Skip to main content
SpringerLink
Log in

Methotrexate Therapy

  • Chapter
Pediatric Inflammatory Bowel Disease

  • 819 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–29.

    Article  PubMed  CAS  Google Scholar 

  2. Nieuwenhuis EE, Blumberg RS. The role of the epithelial barrier in inflammatory bowel disease, In:Blumberg RE, Neurath MF, editors. Immune mechanisms in inflammatory bowel disease. Springer Science, Landes Bioscience, 2005;109–116.

    Google Scholar 

  3. Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn’s disease. Am J Gastroenterol 2003;98:S1–S5.

    Article  PubMed  Google Scholar 

  4. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol 2006;4:1124–29.

    Article  PubMed  CAS  Google Scholar 

  5. Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulatory use as early therapy in pediatric Crohn disease. J Clin Gastroenterol 2006;40:145–148.

    Article  PubMed  CAS  Google Scholar 

  6. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000;119:895–902.

    Article  PubMed  CAS  Google Scholar 

  7. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813–21.

    Article  PubMed  CAS  Google Scholar 

  8. Panaccione R. Methotrexate: lessons from rheumatology. Can J Gastroenterol 2005;9:541–42.

    Google Scholar 

  9. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn disease. The North American Crohn study group investigators. N Engl J Med 1995;332:292–97.

    Article  PubMed  CAS  Google Scholar 

  10. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn study group investigators. N Engl J Med 2000;342:1627–32.

    Article  PubMed  CAS  Google Scholar 

  11. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of Methotrexate in Pediatric Crohn’s Disease: A French Multicenter Study. Inflamm Bowel Dis 2006;12:1053–57.

    Article  PubMed  CAS  Google Scholar 

  12. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric crohn’s disease. Am J Gastroenterol 2007;102:1–9.

    Article  Google Scholar 

  13. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416–21.

    Article  PubMed  CAS  Google Scholar 

  14. Baron TH, Truss CD, Elson CO. Low-dose methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851–56.

    Google Scholar 

  15. Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th edition. New York: McGraw-Hill, 1996;1243–47.

    Google Scholar 

  16. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36–43.

    PubMed  CAS  Google Scholar 

  17. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9–18.

    Article  PubMed  CAS  Google Scholar 

  18. Paillot R, Genestier L, Fournel S, et al. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc 1998;30:2348–2350.

    Article  PubMed  CAS  Google Scholar 

  19. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247–57.

    Google Scholar 

  20. Johnston A, Gudjonsson JE, Sigmundskottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation of adhesion molecules. Clin Immunol 2005;114:154–63.

    Article  PubMed  CAS  Google Scholar 

  21. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739–55.

    Article  PubMed  CAS  Google Scholar 

  22. vanDieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van derWoude J. Revisiting the immunomodulators tacrolimus. Methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006;12:311–27.

    Article  Google Scholar 

  23. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2004;98:530–37.

    Article  Google Scholar 

  24. Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in ciruculating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheum 1999;17:313–20.

    CAS  Google Scholar 

  25. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn disease: long-term safety and toxicity. Am J Gastroenterol 2000;95:1730–34.

    PubMed  CAS  Google Scholar 

  26. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn disease. Aliment Pharmacol Ther 2001;15:35–44.

    Article  PubMed  CAS  Google Scholar 

  27. Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn disease. Aliment Pharmacol Ther 2003;18:57–63.

    Article  PubMed  CAS  Google Scholar 

  28. Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N, Adamson PC. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Peditr Gastroenterol Nutr 2005;40:445–49.

    Article  CAS  Google Scholar 

  29. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn disease. Cochrane Database Syst Rev 2005;1:CD003459.

    PubMed  Google Scholar 

  30. Alsufyani K, Ortiz-Alvarez O, Cabral DA, tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004;31:179–82.

    PubMed  CAS  Google Scholar 

  31. Kozarek RA, Patterson DJ, Gelfand MD, Alin Botoman A, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:335–56.

    Google Scholar 

  32. Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997;11:569–73.

    Article  PubMed  CAS  Google Scholar 

  33. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn disease: a randomized, investigator-blind study. Dig Liver Dis 2003;35:619–27.

    Article  PubMed  CAS  Google Scholar 

  34. Mate-Jimenez J, Hermida C, Canter-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227–33.

    PubMed  CAS  Google Scholar 

  35. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn disease after 6-mercaptopurine. J Pediatr 1998;132:830–35.

    Article  PubMed  CAS  Google Scholar 

  36. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849–57.

    Article  PubMed  CAS  Google Scholar 

  37. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The pediatric rheumatology collaborative study group and the cooperative children’s study group. N Engl J Med 1992;326:1043–49.

    Article  PubMed  CAS  Google Scholar 

  38. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468–73.

    Article  PubMed  CAS  Google Scholar 

  39. Batres LA, Gabriel CA, Tsou VM. Methotrexate-induced esophagitis in a child with crohn disease. J Pediatr Gastroenterol Nutr 2003;37:514–16.

    Article  PubMed  Google Scholar 

  40. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988;19:145–56.

    PubMed  Google Scholar 

  41. Kremer JM, Alarcon GS, Lightfood RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guideline for monitoring liver toxicity. Arthritis Rheum 1994;37:316–28.

    Article  PubMed  CAS  Google Scholar 

  42. Kugathasan S, Newman AJ, Dahms BB, Boyle JT. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term weekly methotrexate therapy. J Pediatr 1996;128:149–51.

    Article  PubMed  CAS  Google Scholar 

  43. Te HS, Schiano TD, Hanauer SB, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150–56.

    Article  PubMed  CAS  Google Scholar 

  44. Rains CP, Noble S, Faulds D. Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137–56.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Director, Pediatric Gastroenterology, Atlantic Health/Goryeb Children’s Hospital, UMD—New Jersey Medical School, 100 Madison Avenue, Morristown, NJ 07962, USA

    Joel R. Rosh (Associate Professor of Pediatrics)

Authors
  1. Joel R. Rosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Attending Physician, Division of GI Hepatology and Nutrition, Director Endoscopy Suite, The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Petar Mamula M.D. (Assistant Professor of Pediatrics) (Assistant Professor of Pediatrics)

  2. Attending Physician, Children’s Center for Digestive Health, Greenville Hospital System University Medical Center, University of South Carolina School of Medicine, Greenville, South Carolina, USA

    Jonathan E. Markowitz M.D., M.S.C.E. (Associate Professor of Clinical Pediatrics) (Associate Professor of Clinical Pediatrics)

  3. Attending Physician and Director, Inflammatory Bowel Disease Center Division of GI, Hepatology and Nutrition. The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Robert N. Baldassano M.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rosh, J.R. (2008). Methotrexate Therapy. In: Mamula, P., Markowitz, J.E., Baldassano, R.N. (eds) Pediatric Inflammatory Bowel Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-73481-1_30

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-73481-1_30

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-73480-4

  • Online ISBN: 978-0-387-73481-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation